These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1178 related articles for article (PubMed ID: 32157661)

  • 1. Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes.
    Zhu T; Goodarzi MO
    Curr Nutr Rep; 2020 Jun; 9(2):83-93. PubMed ID: 32157661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Gut Microbial Endocrine Organ in Type 2 Diabetes.
    Massey W; Brown JM
    Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33373432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-Microbial Metabolites, Probiotics and Their Roles in Type 2 Diabetes.
    Zhai L; Wu J; Lam YY; Kwan HY; Bian ZX; Wong HLX
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?
    Sircana A; Framarin L; Leone N; Berrutti M; Castellino F; Parente R; De Michieli F; Paschetta E; Musso G
    Curr Diab Rep; 2018 Sep; 18(10):98. PubMed ID: 30215149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota-derived metabolites as central regulators in metabolic disorders.
    Agus A; Clément K; Sokol H
    Gut; 2021 Jun; 70(6):1174-1182. PubMed ID: 33272977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of microbial amino acid metabolism in host metabolism.
    Neis EP; Dejong CH; Rensen SS
    Nutrients; 2015 Apr; 7(4):2930-46. PubMed ID: 25894657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
    Huda MN; Kim M; Bennett BJ
    Front Endocrinol (Lausanne); 2021; 12():632335. PubMed ID: 33897618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota and Cardiovascular Disease.
    Witkowski M; Weeks TL; Hazen SL
    Circ Res; 2020 Jul; 127(4):553-570. PubMed ID: 32762536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiome and type 2 diabetes: where we are and where to go?
    Sharma S; Tripathi P
    J Nutr Biochem; 2019 Jan; 63():101-108. PubMed ID: 30366260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.
    Wu J; Yang K; Fan H; Wei M; Xiong Q
    Front Endocrinol (Lausanne); 2023; 14():1114424. PubMed ID: 37229456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between gut microbiome and cardiovascular disease.
    Peng J; Xiao X; Hu M; Zhang X
    Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
    Kootte RS; Vrieze A; Holleman F; Dallinga-Thie GM; Zoetendal EG; de Vos WM; Groen AK; Hoekstra JB; Stroes ES; Nieuwdorp M
    Diabetes Obes Metab; 2012 Feb; 14(2):112-20. PubMed ID: 21812894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding connections and roles of gut microbiome in cardiovascular diseases.
    Rajendiran E; Ramadass B; Ramprasath V
    Can J Microbiol; 2021 Feb; 67(2):101-111. PubMed ID: 33079568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gut microbiota as a novel regulator of cardiovascular function and disease.
    Battson ML; Lee DM; Weir TL; Gentile CL
    J Nutr Biochem; 2018 Jun; 56():1-15. PubMed ID: 29427903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases.
    Neves AL; Chilloux J; Sarafian MH; Rahim MB; Boulangé CL; Dumas ME
    Curr Opin Pharmacol; 2015 Dec; 25():36-44. PubMed ID: 26531326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications.
    Zhao L; Lou H; Peng Y; Chen S; Zhang Y; Li X
    Endocrine; 2019 Dec; 66(3):526-537. PubMed ID: 31591683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.
    Lavelle A; Sokol H
    Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):223-237. PubMed ID: 32076145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus.
    Du L; Li Q; Yi H; Kuang T; Tang Y; Fan G
    Biomed Pharmacother; 2022 May; 149():112839. PubMed ID: 35325852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles.
    Abdul Rahim MBH; Chilloux J; Martinez-Gili L; Neves AL; Myridakis A; Gooderham N; Dumas ME
    Acta Diabetol; 2019 May; 56(5):493-500. PubMed ID: 30903435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.